Background Drug-coated balloons (DCB) are a novel therapeutic strategy for small native
coronary artery disease. However, their safety and efficacy is poorly defined in comparison …

Background In the treatment of de-novo coronary small vessel disease, drug-coated
balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up …

Objectives: The aim of this study was to evaluate the angiographic efficacy and clinical
outcomes of the Restore paclitaxel-coated balloon in a randomized trial designed to enable …

Background: Patients at high-bleeding risk (HBR) undergoing percutaneous coronary
intervention represent a challenging patient population. The use of drug-coated balloon …

Objectives The study sought to evaluate the impact of diabetes mellitus on 3-year clinical
outcome in patients undergoing drug-coated balloon (DCB) or drug-eluting stent (DES) …

Background: Drug-coated balloons (DCBs) are an established treatment strategy for
coronary artery disease. Randomized data on the application of DCBs in patients with an …

Background and objectives Recent data have established non-inferiority of drug-coated
balloons (DCB) compared to drug-eluting stents (DES) for treatment of small-vessel …

Background Data on the safety and efficacy of drug-coated balloon (DCB) compared to drug-
eluting stent (DES) in patients with chronic kidney disease (CKD) are scarce, particularly at …

Results Overall, 758 patients were enrolled in this analysis, of which 437 (58%) had very
small vessel disease. There were similar results in both treatment groups for the primary …

Objective To assess the determinants of target lesion revascularization (TLR) after drug-
coated balloon (DCB) angioplasty for de novo small coronary artery lesions. Methods This …